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COPD

:   chronic obstructive pulmonary disease

IAA

:   Innovative Asthma Association

ICS

:   inhaled corticosteroid

IgE

:   immunoglobulin E

LABA

:   inhaled long‐acting beta‐agonist

PEF

:   peak expiratory flow

SABA

:   short‐acting beta‐agonist

SpO~2~

:   oxygen saturation by pulse oximetry

VAS

:   visual analogue scale

1. INTRODUCTION {#all13374-sec-0006}
===============

Risk factors for incipient asthma exacerbation include sex, age, race, socioeconomic status, baseline lung function, smoking history, exposure to viruses, active sinusitis, and symptomatic gastroesophageal reflux disease.[1](#all13374-bib-0001){ref-type="ref"} Frequent asthma exacerbation is a risk factor associated with progression to severe disease and excessive decline in lung function.[2](#all13374-bib-0002){ref-type="ref"} Severe exacerbation is recognized as an indication for evaluating the required level of interventional asthma management to reduce the potential risk of death.[3](#all13374-bib-0003){ref-type="ref"}, [4](#all13374-bib-0004){ref-type="ref"}, [5](#all13374-bib-0005){ref-type="ref"}, [6](#all13374-bib-0006){ref-type="ref"}, [7](#all13374-bib-0007){ref-type="ref"}, [8](#all13374-bib-0008){ref-type="ref"} Using cluster analysis, many studies have described the heterogeneity of severe asthma symptoms during nonexacerbation periods.[1](#all13374-bib-0001){ref-type="ref"}, [9](#all13374-bib-0009){ref-type="ref"}, [10](#all13374-bib-0010){ref-type="ref"}, [11](#all13374-bib-0011){ref-type="ref"}, [12](#all13374-bib-0012){ref-type="ref"} However, to the best of our knowledge, no studies have reported on the heterogeneity of patient factors preceding worsening symptoms leading to severe or life‐threatening exacerbation in a real‐world setting.

Previous reports to date have relied on information extracted by physicians from limited medical histories and on information provided by relatives or friends of patients who died from severe asthma.[3](#all13374-bib-0003){ref-type="ref"}, [4](#all13374-bib-0004){ref-type="ref"}, [5](#all13374-bib-0005){ref-type="ref"} Other studies have shown that short‐acting beta‐agonist (SABA) usage was increased from around 5 days preceding emergency hospitalization.[13](#all13374-bib-0013){ref-type="ref"}, [14](#all13374-bib-0014){ref-type="ref"} However, these previous data were from strictly controlled clinical trials with good compliance to inhaled corticosteroid (ICS) or ICS/long‐acting beta‐agonist (LABA) use, while in general clinical practice, variable asthma drug compliance and smoking habits prevail as confounding factors. To accurately predict and reduce exacerbation, it is necessary to determine the factors influencing the pattern of exacerbation in a real‐world setting and adjust management strategies for each patient accordingly.

We recently performed a nationwide, prospective, multicenter study in which patients admitted for severe or life‐threatening asthma were recruited at emergency hospitals throughout Japan.[15](#all13374-bib-0015){ref-type="ref"} The results demonstrated that significant heterogeneity exists among patients with severe or life‐threatening asthma exacerbation. We further estimated trajectories of asthma symptoms using *k*‐means for longitudinal data in this study.

Inaccurate assessment of asthma severity often delays the provision of an appropriately intensive treatment, consequently leading to hospital admission or even death. In recent real‐world adult asthma studies, symptoms assessed by visual analogue scale (VAS) scoring have been proposed as potentially reliable tools for managing patients more effectively and for predicting uncontrolled asthma at home or the general practitioner\'s office.[16](#all13374-bib-0016){ref-type="ref"}, [17](#all13374-bib-0017){ref-type="ref"}, [18](#all13374-bib-0018){ref-type="ref"} To predict, prevent, and manage severe or life‐threatening asthma exacerbation, we herein assessed serial VAS scores from the 14 days before emergency hospitalization and sought to identify predictors of asthma worsening using cluster analysis.

2. METHODS {#all13374-sec-0007}
==========

2.1. Study setting {#all13374-sec-0008}
------------------

This study was a secondary analysis of a previously reported prospective, multicenter, observational study of patients with severe or life‐threatening asthma exacerbation.[15](#all13374-bib-0015){ref-type="ref"} In the previous study[15](#all13374-bib-0015){ref-type="ref"}, we did not analyze the serial asthma symptom using 10 cm VAS scores. This study was conducted by the Innovative Asthma Association (IAA), a nationwide group performing research across Japan. Patients were recruited from 17 hospitals between October 2011 and December 2012. Briefly, all eligible patients met the following criteria: (i) \>16 years of age; (ii) requiring hospitalization due to severe or life‐threatening asthma attacks with SpO~2~ \<90% on room air at the time of hospitalization or emergency transport before treatment, and (iii) no heart failure, pneumonia, pneumothorax, or other pulmonary diseases on X‐ray. Severe or life‐threatening exacerbation was defined according to the Japanese Society of Allergology guidelines,[19](#all13374-bib-0019){ref-type="ref"} that is, an inability to move because of dyspnea, difficulty in speaking, and the following objective findings: peak expiratory flow (PEF) \<60%, SpO~2~ \<90%, partial pressure of oxygen in arterial blood (PaO~2~) ≤60 mm Hg, and partial pressure of carbon dioxide in arterial blood (PaCO~2~) ≥45 mm Hg.

The study was reviewed and approved by the Ethics Committee of Sapporo Medical University (No. 23‐47). The study protocol is registered with the University Hospital Medical Information Network in Japan (number 000006448).

2.2. Questionnaire {#all13374-sec-0009}
------------------

A total of 173 variables were acquired consisting of 91 patient‐reported questions and 82 physician‐reported questions during admission period (see Supplementary Appendices 1 and 2 of the Supporting Information in reference [15](#all13374-bib-0015){ref-type="ref"}). The patient‐reported questionnaires were mainly used to obtain baseline information on risk factors, demographics, and asthma at baseline. The physician‐reported questionnaires were mainly used to record clinical and laboratory findings and follow‐up data on admission. The severity of asthma was determined by the physician according to symptomatic evaluation and the daily medication regimen according to the GINA guidelines 2005.[20](#all13374-bib-0020){ref-type="ref"}

2.3. Serial VAS {#all13374-sec-0010}
---------------

Self‐administered serial VAS of asthma symptoms comprising a 10‐cm‐long vertical segment was completed retrospectively, daily from 14 days before admission (day −14) to day −3, and then at −60, −48, −36, −24, −12, −6, and −3 hours, and finally at 0 hours (on admission). The patient was asked to indicate his/her actual perception of asthma symptoms by marking a point along the segment. In this study, a score of 0 corresponded to optimal symptom‐free breathing, whereas 10 corresponded to the most severe asthmatic symptoms. Mild asthma exacerbation (0 \< VAS ≤ 3.3) was defined as "wheeze or cough," "can lie down," and "daily life not disturbed"; moderate asthma exacerbation (3.3 \< VAS ≤ 6.6) was defined as "cannot lie down," "mildly disturbed daily life," and "mild dyspnea sensation"; finally, severe exacerbation (6.6 \< VAS ≤ 10) was defined as "cannot move," "cannot speak," and "strong dyspnea." These "mild," "moderate," and "severe" categories were depicted by dotted lines on the VAS score sheet (Figures [S1](#all13374-sup-0001){ref-type="supplementary-material"} and [S2](#all13374-sup-0001){ref-type="supplementary-material"}).

2.4. Statistical analysis {#all13374-sec-0011}
-------------------------

Clusters (or trajectories) for the longitudinal VAS scores were estimated using *k*‐means for longitudinal data.[21](#all13374-bib-0021){ref-type="ref"}, [22](#all13374-bib-0022){ref-type="ref"}, [23](#all13374-bib-0023){ref-type="ref"} This nonparametric procedure partitions cases into clusters. Each case is first assigned arbitrarily to 1 initial cluster. Next, each case is reassigned to the neighborhood cluster based on the center (average) of each cluster. The operation is repeated until that there is no change by mean adjustment in the clusters. This process to convergence is then repeated. The best cluster number is determined by clinical interpretability and a criterion that maximizes a ratio computed by dividing between variance by within variance (ie, maximizing the homogeneity within clusters and maximizing the differences between clusters). Missing VAS scores (\<4% of total) were appropriately treated by linear interpolation. The interpolated VAS scores were divided by 10 and subjected to log‐log transformation, and these values were then used in the cluster analysis.

Additionally, differences in characteristics at admission between clusters were tested using the Kruskal‐Wallis test for continuous variables and the chi‐square test for categorical variables. To construct a decision tree for identifying specific clusters, we performed a tree‐based recursive partitioning by conditional inference. Analyses were performed using R version 3.3.2 (R Foundation, Vienna, Austria) with the functions "kml" (package: kml) and "ctree" (package: party).

3. RESULTS {#all13374-sec-0012}
==========

Patients meeting the eligibility criteria during the study period numbered 223 recruited from 17 hospitals throughout Japan.[15](#all13374-bib-0015){ref-type="ref"} Thirty‐three patients were excluded because the attending physicians considered it inappropriate to include them in the study. Thus, cluster analysis was performed on 190 patients (Figure [1](#all13374-fig-0001){ref-type="fig"}). Of these, 50% had a history of prior hospitalization for asthma exacerbation (Table [1](#all13374-tbl-0001){ref-type="table"}), and all of them had been admitted to the hospital emergency room with SpO~2~ \<90%, allowing us to exclude psychosomatic exacerbation and other diseases such as vocal cord dysfunction. The 190 asthmatic patients were clustered into 3 separate groups according to serial VAS scores. These were characterized by rapidly (cluster A), fairly rapidly (cluster B), and slowly (cluster C) worsening asthma symptoms. Trajectories of changes in median VAS values of the 3 clusters in the total of 190 subjects from the day −14 up to hospital admission are shown in Figure [2](#all13374-fig-0002){ref-type="fig"}. Asthma symptoms by VAS scoring gradually worsened from the day −8 to −6 before admission. The median VAS score reached 3.3 cm approximately 24 hours before subsequent admission in all 190 patients. A VAS score of 3.3 cm represents the border between mild and moderate exacerbations. Histograms of the VAS score at day −6, −6 hours, −3 hours before admission, and 0 hours (at admission) for each cluster are depicted in Figure [3](#all13374-fig-0003){ref-type="fig"}. Demographic characteristics, comorbidities, usual symptom triggers, current asthma condition, current triggers, and drug usage of patients in these 3 clusters are shown in Tables [1](#all13374-tbl-0001){ref-type="table"}, [2](#all13374-tbl-0002){ref-type="table"}, and [S1](#all13374-sup-0001){ref-type="supplementary-material"}.

![Patient characteristics](ALL-73-1110-g001){#all13374-fig-0001}

###### 

Demographic characteristics, comorbid diseases, and baseline asthma in each cluster

  Variables and characteristics, N = 190                 Cluster A (n = 80)   Cluster B (n = 76)   Cluster C (n = 34)   *P*‐value
  ------------------------------------------------------ -------------------- -------------------- -------------------- -----------
  Demographic characteristics                                                                                           
  Female, n (%)                                          40 (50)              45 (59)              23 (68)              .190
  Age (y), mean ± SD                                     51 ± 17              63 ± 18              59 ± 17              \<.001
  Up to 41 y                                             23 (29)              11 (14)              5 (15)               \<.001
  41 y to \<65 y                                         38 (48)              21 (28)              15 (44)              
  \>65 y                                                 19 (24)              44 (58)              14 (41)              
  BMI \<18.5 kg/m^2^, n (%)                              20 (25)              7 (9)                3 (8)                .015
  BMI ≥30.0 kg/m^2^, n (%)                               8 (10)               5 (7)                5 (15)               .285
  Lifetime smoker, n (%)                                 59 (74)              42 (55)              21 (62)              .052
  Current smoker, n (%)                                  42 (53)              18 (24)              11 (32)              \<.001
  Pack‐year, mean ± SD                                   18 (19)              15 (22)              18 (25)              .145
  Pet ownership, n (%)                                   29 (36)              18 (24)              11 (32)              .227
  Hypersensitivity symptoms to furred pets, n (%)        26 (33)              8 (11)               7 (21)               .004
  Comorbid diseases, n (%)                                                                                              
  Allergic rhinitis                                      41 (51)              36 (47)              15 (44)              .763
  Atopic eczema                                          9 (11)               9 (12)               2 (6)                .618
  Chronic hyperplastic rhinosinusitis/nasal polyposis    21 (26)              22 (29)              10 (29)              .910
  Diabetes                                               8 (10)               11 (15)              4 (12)               .692
  Hyperlipidemia                                         4 (5)                19 (25)              4 (12)               .002
  Hypertension                                           18 (23)              23 (30)              6 (18)               .304
  Chronic obstructive pulmonary disease                  8 (10)               11 (15)              5 (15)               .648
  Inactive pulmonary tuberculosis                        3 (4)                6 (8)                2 (6)                .541
  Any psychological diseases                             7 (9)                2 (3)                0 (0)                .071
  Baseline asthma                                                                                                       
  Asthma duration, mean ± SD                             17 ± 14              21 ± 20              18 ± 18              .709
  Severity, n (%)                                                                                                       
  Intermittent                                           29 (36)              25 (33)              11 (32)              .803
  Mild persistent                                        14 (18)              17 (22)              4 (12)               
  Moderate persistent                                    22 (28)              18 (24)              9 (26)               
  Severe persistent                                      15 (19)              16 (21)              10 (29)              
  Aspirin‐intolerant asthma, n (%)                       3 (3.8)              0 (0.0)              2 (5.9)              .146
  Previous asthma exacerbation, n (%)                                                                                   
  Unscheduled visits in the past year (≥once)            34 (43)              31 (41)              15 (44)              .944
  History of hospitalization for asthma                  40 (50)              38 (50)              17 (50)              1.000
  Hospitalizations for asthma in the past year (≥once)   16 (20)              13 (17)              5 (15)               .775
  History of NFA requiring mechanical ventilation        6 (8)                6 (8)                2 (6)                .939
  Usual trigger of worsening of symptoms, n (%)                                                                         
  Exposure to irritant                                   37 (46)              32 (42)              21 (62)              .156
  Dampness/storm                                         25 (31)              20 (26)              11 (32)              .733
  Alcohol/meal                                           18 (23)              18 (24)              7 (21)               .937
  Cold air/climate change,                               59 (74)              41 (54)              25 (74)              .019
  Strain/stress                                          50 (63)              40 (53)              23 (68)              .256
  Exposure to furred pets                                17 (21)              6 (8)                5 (15)               .063
  Exposure to house dust                                 31 (39)              21 (28)              13 (38)              .295

BMI, body mass index; NFA, near‐fatal asthma.
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![Trajectories of median 10 cm visual analogue scale values from the 14 d before hospital admission for severe or life‐threatening asthma exacerbation](ALL-73-1110-g002){#all13374-fig-0002}

![Serial changes in histogram of 10 cm visual analogue scale values at −6 d, −6 h, −3 h, and 0 h before hospital admission in each cluster](ALL-73-1110-g003){#all13374-fig-0003}

###### 

Asthma symptoms and medication usage before hospitalization in each cluster

  Variable, N = 190                                                        Cluster A (n = 80)   Cluster B (n = 76)   Cluster C (n = 34)   *P*‐value
  ------------------------------------------------------------------------ -------------------- -------------------- -------------------- -----------
  Asthma symptoms in the previous 3 mo                                                                                                    
  Daytime symptoms, n (%)                                                                                                                 
  Absent                                                                   18 (23)              26 (35)              10 (29)              .093
  Less than once a week                                                    34 (43)              23 (31)              7 (21)               
  Once or more a week, not every day                                       20 (25)              17 (23)              8 (24)               
  Every day                                                                8 (10)               9 (12)               9 (27)               
  Limitation of activities, n (%)                                                                                                         
  Absent                                                                   17 (22)              26 (35)              10 (29)              .151
  Mild and brief                                                           42 (53)              31 (41)              12 (35)              
  Disturbs daily life or sleep ≥once a month                               5 (6)                8 (11)               2 (6)                
  Disturbs daily life or sleep ≥once a week                                14 (18)              7 (9)                7 (21)               
  Restricts daily life                                                     1 (1)                3 (4)                3 (9)                
  Nocturnal symptoms/awakening, n (%)                                                                                                     
  Absent                                                                   39 (51)              47 (63)              20 (61)              .117
  Less than twice a month                                                  20 (26)              11 (15)              2 (6)                
  Twice or more a month                                                    5 (7)                6 (8)                2 (6)                
  Once or more a week                                                      7 (9)                4 (5)                2 (6)                
  Frequently                                                               5 (7)                7 (9)                7 (21)               
  Drug use in the previous month                                                                                                          
  ICS, n (%)                                                                                                                              
  Do not use                                                               30 (38)              25 (33)              13 (38)              .047
  Less than once per week                                                  10 (13)              3 (4)                2 (6)                
  Occasionally (1‐3 d per week)                                            11 (14)              3 (4)                4 (12)               
  Almost every day (≥4 d per week)                                         29 (36)              45 (59)              15 (44)              
  SABA, n (%)                                                                                                                             
  Do not use                                                               35 (44)              38 (50)              18 (53)              .197
  Less than once per week                                                  13 (16)              15 (20)              3 (9)                
  Occasionally (1‐3 d per week)                                            23 (29)              12 (16)              5 (15)               
  Almost every day (≥4 d per week)                                         9 (11)               11 (15)              8 (24)               
  OCS regular use[a](#all13374-note-0005){ref-type="fn"}, n (%)            4 (5)                9 (12)               3 (9)                .272
  LTRA regular use[a](#all13374-note-0005){ref-type="fn"}, n (%)           20 (25)              20 (26)              13 (38)              .345
  LABA regular use[a](#all13374-note-0005){ref-type="fn"}, n (%)           26 (33)              34 (45)              15 (44)              .255
  Theophylline regular use[a](#all13374-note-0005){ref-type="fn"}, n (%)   9 (11)               19 (26)              4 (12)               .059
  SABA usage in the previous week, n (%)                                                                                                  
  Do not use                                                               35 (44)              38 (50)              18 (53)              .399
  Less than once per week                                                  7 (9)                4 (5)                0 (0)                
  Occasionally (1‐3 d per week)                                            17 (21)              16 (21)              4 (12)               
  Almost every day (≥4 d per week)                                         21 (26)              18 (24)              12 (35)              

ICS, inhaled corticosteroid; SABA, short‐acting beta‐agonist; OCS, oral corticosteroid; LTRA, leukotriene receptor antagonist; LABA, long‐acting beta‐agonist.

Patients who reported use of the drug almost every day (≥4 d per week).
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The characteristics of cluster A were a rapidly worsening state (n = 80, 42.1%); median VAS score reached 3.3 or 6.6 cm by 7.4 or 2.7 hours before admission, respectively (Figure [2](#all13374-fig-0002){ref-type="fig"}). The VAS score at admission was 10 cm in 100% of patients in this cluster (Figure [3](#all13374-fig-0003){ref-type="fig"}). The trigger for current exacerbation given as "stopped using anti‐asthma medication" was most frequent in cluster A relative to the other 2 clusters (*P* = .003, Table [S1](#all13374-sup-0001){ref-type="supplementary-material"}). Patients in cluster A were lean (25% with a body mass index \<18.5), young or middle‐aged (mean 51 year), had poor compliance with anti‐asthma medication (only 36% of patients used their ICS 4 or more days a week), were current smokers (53%), and were allergic to furred pets, mites, and moths, sensitive to cold air or other climate variations (Tables [1](#all13374-tbl-0001){ref-type="table"}, [2](#all13374-tbl-0002){ref-type="table"} and [S1](#all13374-sup-0001){ref-type="supplementary-material"}). It was founded a tendency (*P* = .071) for cluster A to have more psychological diseases; 6 of depression and 1 anxiety, as compared with cluster B and C (Table [1](#all13374-tbl-0001){ref-type="table"}). A tree diagram separating cluster A from B and C is shown in Figure [S3](#all13374-sup-0001){ref-type="supplementary-material"}.

In contrast, patients in cluster B had rapid worsening (n = 76, 40.0%) with the median duration of 48 and 8.7 hours from the time of the VAS score reaching 3.3 and 6.6 cm, respectively, to the time of admission (Figure [2](#all13374-fig-0002){ref-type="fig"}). They were middle‐aged or older (63 year), with comorbidities including hyperlipidemia (25%) and high hemoglobin A~1c~ (*P* = .022), and had relatively good ICS or ICS/LABA compliance, but with a reduced sensation of dyspneic deterioration (Tables [1](#all13374-tbl-0001){ref-type="table"} and [S2](#all13374-sup-0001){ref-type="supplementary-material"}). Even at admission, 45% perceived mild‐to‐moderate dyspnea (Figure [3](#all13374-fig-0003){ref-type="fig"}), with the lowest arterial blood oxygen concentration of all 3 clusters, at a mean PaO~2~ of 72 Torr ([Table S1](#all13374-sup-0001){ref-type="supplementary-material"}).

Finally, cluster C (n = 34, 17.9%) consisted of patients with slowly worsening symptoms, with periods of approximately 10 days and 12 hours from the time of the VAS score reaching 3.3 and 6.6 cm, respectively, until admission (Figure [2](#all13374-fig-0002){ref-type="fig"}). They were predominantly middle‐aged (59 year) women (68%) of whom 32% were current smokers. The most characteristic features of this cluster were mild‐to‐moderate asthma symptoms manifesting daily, despite quite good compliance with ICS use. Severe asthmatic symptoms (VAS \> 6.6) were already present in 94% patients 6 hours before admission, in contrast to 25% in cluster A, and only 8% in cluster B (Figure [3](#all13374-fig-0003){ref-type="fig"}).

These characteristics and the exacerbation status of patients in the 3 clusters are summarized in Table [3](#all13374-tbl-0003){ref-type="table"}. Additionally, it can be stated that there were no differences among these patients regarding maximum oxygen inhalation dose, duration of supplemental oxygen, or duration of hospitalization (data not shown). There was no seasonal variation of the frequency of each cluster (data not shown).

###### 

Summary of the characteristics of patients in each cluster

  Variable, N = 190                          Cluster A                                                Cluster B   Cluster C   
  ------------------------------------------ -------------------------------------------------------- ----------- ----------- ----------
  Demographics                               Age, mean, years                                         51          63          59
  up to 41 y                                 ++                                                       \+          \+          
  41 y to \<65 y                             +++                                                      ++          ++          
  ≥65 y                                      \+                                                       +++         ++          
  BMI \<18.5 kg/m^2^                         +++                                                      −           −           
  Current smoker                             +++                                                      \+          ++          
  Hypersensitivity symptoms to furred pets   ++                                                       \+          \+          
  Comorbidity                                Hyperlipidemia                                           −           ++          \+
  Usual trigger of worsening of symptoms     Cold air/climate change, (%)                             +++ (74)    +++ (54)    +++ (74)
  Drug usage in the previous month           ICS regular use[a](#all13374-note-0008){ref-type="fn"}   ++          +++         ++
  Trigger of the current exacerbation        Stop using anti‐asthma medication                        \+          −           −
  Time to hospitalization                    From VAS3.3, median, hour                                7.4         48.0        240.0
  From VAS6.6, median, hour                  2.7                                                      8.7         12.0        

ICS, inhaled corticosteroid; BMI, body mass index; VAS, visual analogue scale.

−, \<10%, + 10‐\<25%; ++, 25‐\<50%; +++, 50‐\<75%, ++++, 75%‐100%.

Patients who reported use of the drug almost every day (≥4 d per week) of ICS use in the previous month in Table [2](#all13374-tbl-0002){ref-type="table"}.
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4. DISCUSSION {#all13374-sec-0013}
=============

The work presented here is a secondary analysis of our previous study,[15](#all13374-bib-0015){ref-type="ref"} representing details of the events that occur shortly before and during severe or life‐threatening asthma exacerbation. Our results document a gradual increase in the VAS score for asthmatic symptoms over 6‐8 days before hospital admission, to hospital, leading to moderate severity (VAS \> 3.3) at 24 hours before admission in all 190 patients surveyed (Figure [2](#all13374-fig-0002){ref-type="fig"}). These results are consistent with a previous study by Tattersfield et al.[13](#all13374-bib-0013){ref-type="ref"} reported a gradual decline PEF over 5‐7 days associated with severe exacerbation. These investigators also reported that changes in PEF, asthma symptoms, and use of rescue beta‐agonists before exacerbation occurred in a parallel manner. Herein, using serial VAS scores of asthma symptoms, we have identified 3 groups of patients with diverse backgrounds but showing distinct characteristics leading up to severe or life‐threatening exacerbation. As assessed in a real‐world setting rather than a controlled trial, these patients fell into 3 groups with rapid, fairly rapid, or slow progression. We found that there were no differences among these 3 clusters in overuse of SABA before admission, baseline asthma severity, comorbid chronic obstructive pulmonary disease (COPD), or outcome after hospital admission. Interestingly, there were differences in ICS or ICS/LABA compliance, perception of dyspnea, and baseline hypersensitivity to environmental stimuli. These findings imply that optimal personalized management regimens, aimed at preventing severe or life‐threatening asthma exacerbation in normal daily life, would differ even among patients within these clusters.

We found that patients assigned to cluster A showed rapid worsening just hours before moderate asthma attack and required emergency admission. Nonetheless, their subjective perception of asthma symptoms was essentially accurate, as reflected by their VAS score being 10 cm on admission for all patients in cluster A (Figure [3](#all13374-fig-0003){ref-type="fig"}). They were lean young or middle‐aged patients with poor anti‐asthma medication compliance, were smokers, and were allergic to furred pets, mites, and moths, sensitive to cold air and other climate changes (Tables [1](#all13374-tbl-0001){ref-type="table"}, [2](#all13374-tbl-0002){ref-type="table"} and [S2](#all13374-sup-0001){ref-type="supplementary-material"}). This cluster is thus characterized by rapidly worsening airway inflammation associated with smoking and cessation of ICS or ICS/LABA, with consequently enhanced responses to environmental triggers, potentially leading to rapid deterioration and asthma exacerbation. Not surprisingly, ICS or ICS/LABA noncompliance and smoking both increase asthma exacerbations.[11](#all13374-bib-0011){ref-type="ref"}, [12](#all13374-bib-0012){ref-type="ref"}, [24](#all13374-bib-0024){ref-type="ref"} Williams et al.[10](#all13374-bib-0010){ref-type="ref"} reported that ICS or ICS/LABA compliance rates exceeding 75% of the prescribed dose over 6 months appeared to represent a threshold above which moderate asthma exacerbations were significantly reduced. Nonetheless, this was not associated with a decrease in the number of asthma‐related emergency department visits and hospitalizations. Not only better ICS or ICS/LABA compliance but also education to encourage avoidance of environmental triggers would, therefore, be important for decreasing severe or life‐threatening exacerbation in cluster A patients.

Cluster B patients, with a fairly rapid worsening before admission within 48 hours of a moderate asthma attack (VAS = 3.3) or within 8.7 hours of a severe attack (VAS = 6.6) were middle‐aged or older, with hyperlipidemia, relatively good ICS or ICS/LABA compliance, and less perceived dyspnea. The most distinctive feature of patients in cluster B was their low perception of dyspnea during the exacerbation. VAS scores were lower than in clusters A or C even at hospital admission (Figure [3](#all13374-fig-0003){ref-type="fig"}). A low degree of the sensation of dyspnea is recognized as a crucial problem in severe asthma frequently developing into a near‐fatal attack. Our present results are therefore fully consistent with the literature.[25](#all13374-bib-0025){ref-type="ref"}, [26](#all13374-bib-0026){ref-type="ref"} For these patients, objective measurements, that is, daily monitoring of PEF[27](#all13374-bib-0027){ref-type="ref"} or fractional exhaled nitric oxide concentration, may be useful for early detection of exacerbation and recognizing the patient′s actual objective asthmatic status.

Finally, cluster C consisted of patients gradually worsening from VAS = 3.3 and VAS = 6.6 over approximately 10 days and 12 hours, respectively. The most characteristic features of this cluster were mild‐to‐moderate asthmatic symptoms present daily despite relatively good compliance with ICS. Severe symptoms (VAS \> 6.6) were already present in 94% of patients 6 hours before admission (Figure [3](#all13374-fig-0003){ref-type="fig"}). Patients falling into this cluster are unique in that although they had strong perceptions of dyspnea, they failed to seek medical attention before respiratory failure, likely because they had become accustomed to experiencing mild‐to‐moderate symptoms every day. Patients in this cluster shared hypersensitivity to environmental triggers and furred pets with cluster A, as well as smoking. As shown in Table [1](#all13374-tbl-0001){ref-type="table"}, baseline severity of asthma in cluster C patients was not different from the other 2 clusters. Only 29% of cluster C patients had severe persistent asthma poorly controlled by the current standard of care medication; for this subgroup, T‐helper type 2 response‐targeting therapies or other new drugs[28](#all13374-bib-0028){ref-type="ref"} might be considered. However, in most patients in this cluster, avoidance of environmental triggers, education on the necessity for even better ICS or ICS/LABA compliance, and changing to higher dose ICS or ICS/LABA may be effective.

Baseline disease severity of the patients in our study was mild intermittent in 34%, mild persistent in 18%, moderate persistent in 26%, and severe persistent in the remaining 22%, as shown in Table [1](#all13374-tbl-0001){ref-type="table"}. Consistent with previous reports, these findings indicate that severe exacerbation or near‐fatal asthma is not related to baseline asthma severity.[29](#all13374-bib-0029){ref-type="ref"}, [30](#all13374-bib-0030){ref-type="ref"} Surprisingly, 52% of the adult patients in this real‐life setting had mild asthma, and their baseline disease severities did not differ among the 3 clusters (Table [1](#all13374-tbl-0001){ref-type="table"}). In a Japanese study of asthma deaths in adults,[20](#all13374-bib-0020){ref-type="ref"} the most frequent degree of baseline asthma severity was "severe" in 39.2% of cases, followed by "moderate" in 33.0%. On the other hand, in a UK pediatric cohort study, half of asthma deaths were in patients with mild or moderate asthma.[31](#all13374-bib-0031){ref-type="ref"} It was also reported that near‐fatal or severe asthma exacerbations show age‐related differences in clinical presentation.[32](#all13374-bib-0032){ref-type="ref"}, [33](#all13374-bib-0033){ref-type="ref"} In our present study, relative to younger adults (\<41 years), there was a trend toward increasing VAS symptom scores in middle‐aged and elderly patients (≥41 years) between day −8 days and −24 hours before hospitalization. However, there were no differences over the period 12 hours before admission among our 3 groups (data not shown). The clustering was not affected by baseline disease severity or age.

We also found a tendency for patients in cluster A to have more psychological diseases; depression and anxiety, as comparing with cluster B and C (Table [1](#all13374-tbl-0001){ref-type="table"}). As cluster A patients have poor ICS or ICS/LABA compliance, the psychological state might be associated with this poor compliance. Depression and anxiety are known to be important risk factors for severe or near‐fatal asthma.[34](#all13374-bib-0034){ref-type="ref"}, [35](#all13374-bib-0035){ref-type="ref"}, [36](#all13374-bib-0036){ref-type="ref"} Psychosocial stress is well known to evoke asthma exacerbation, either as triggers or as covariates of worse outcomes,[34](#all13374-bib-0034){ref-type="ref"} and strain or stress is also believed to predispose to asthma. In our study, there is no difference in usual triggers of worsening asthma due to strain or stress among 3 clusters (Table [1](#all13374-tbl-0001){ref-type="table"}). Psychosocial problems are very complex, and the relationship between perception of dyspnea sensations and actual asthma exacerbation is especially unclear, indicating the need for further research.

This study does have potential limitations. First, assessment of exacerbation was only carried out once per patient, such that whether a second or third exacerbation would have had the same predictors in each patient could not be determined. However, this study aimed to recognize factors leading to severe or life‐threatening exacerbation. As half of our study population had already experienced the previous hospitalization for severe or life‐threatening exacerbation, detailed medical histories of asthma exacerbations may partially compensate for this limitation. Therefore, long‐term follow‐up of this cohort is needed. Second, our study depends on the reliability of retrospective self‐reporting asthma symptom VAS scoring used in the cluster analysis. Low perception of dyspnea in patients with near‐fatal asthma has been reported in the literature,[25](#all13374-bib-0025){ref-type="ref"}, [26](#all13374-bib-0026){ref-type="ref"} suggesting questionnaire‐based evaluations of symptoms may not necessarily be reliable. Certainly, in this study low perception of dyspnea was prominent in cluster B and high perception of dyspnea in cluster C. Objective measurements of lung function including PEF or fractional exhaled nitric oxide would be helpful for validating our results, but that is not practical in an actual clinical setting. It has also been reported that changes in asthma symptom scores, PEF, and use of rescue beta‐agonists before exacerbation showed parallels.[13](#all13374-bib-0013){ref-type="ref"} Third, in this study we could not address the influence of ethnicity upon our cluster, because all participants are one race of Japanese.

In conclusion, we herein identified 3 distinct clusters of worsening patterns and factors associated with those patterns leading to severe or life‐threatening asthma exacerbation in a real‐life setting rather than in a clinical trial. The most important factors contributing to being assigned to one of these 3 clusters were degree of ICS or ICS/LABA compliance, low or high perception of dyspnea, and baseline hypersensitivity to environmental stimuli, as well as smoking, and sensitivity to furred pets. Combinations of these factors were different for each cluster, such that daily‐life asthma education and treatment action plans should also be explicitly tailored to the patients in each cluster. Another strength of our study is the finding that not only low perception but also high perception of dyspnea is a critical characteristic of incipient severe or life‐threatening asthma exacerbation. Further studies are necessary to assess the usefulness of suggesting phenotypic interventions for the prevention of recurrent severe or life‐threatening asthma exacerbation.
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